KYMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient entry: price is pressing near resistance (R1 77.60 / R2 ~80.10) with short-term overbought momentum (RSI6 ~70.8) and pattern-based odds skewed to near-term weakness (next day/week negative).", "No Intellectia buy-trigger today (no AI Stock Picker or SwingMax), removing the highest-conviction \u201cbuy now\u201d justification.", "Better risk/reward likely comes on a pullback toward the pivot/support zone (73.5) or after a catalyst (next major: earnings 2026-02-25 pre-market)."]
["Trend: Bullish structure overall (SMA_5 > SMA_20 > SMA_200) with MACD histogram positive and expanding (+0.744) \u2192 trend remains up.", "Momentum/extension: RSI_6 at 70.844 (borderline overbought) \u2192 upside may be slower/fragile near-term as buyers look extended.", "Key levels: Pivot support ~73.539; resistance R1 ~77.597 (being tested), then R2 ~80.105. A rejection near R1/R2 increases pullback risk toward pivot.", "Near-term statistical analogs: 50% chance of about -2.17% next day and -3.51% next week, but +5.58% next month \u2192 near-term choppy/soft, medium-term constructive.", "Intellectia Proprietary Trading Signals", "- AI Stock Picker: no signal on given stock today.", "- SwingMax: No signal on given stock recently."]
["Analyst optimism remains strong overall, with multiple large price-target raises after positive KT-621 Phase 1b atopic dermatitis data (supports higher long-term expectations).", "Barclays initiated/assumed coverage with Overweight and a high PT ($133), citing favorable biotech setup and industry tailwinds (M&A, fundamentals).", "Next scheduled catalyst: QDEC 2025 earnings on 2026-02-25 (pre-market) could reset expectations."]
["No fresh news catalysts in the last week \u2192 fewer immediate drivers to push through resistance right now.", "Wolfe Research downgrade to Peer Perform (and removed PT) flags valuation/catalyst gap concerns for 2026, which can cap upside in the near term.", "Technical setup is extended near resistance with RSI near overbought \u2192 higher probability of a pullback before the next leg higher.", "Short-term pattern stats point to mild downside bias over the next day/week."]
["Latest reported quarter: 2025/Q3.", "Revenue: $2.764M, down 26.12% YoY \u2192 top-line is small and volatile (typical for clinical-stage biotech).", "Net income: -$82.175M, improved 31.51% YoY (less negative) \u2192 losses narrowing versus last year.", "EPS: -$0.94, improved 14.63% YoY \u2192 improving per-share loss profile.", "Gross margin: 100% (flat) \u2192 not a key driver at this stage; runway/cash burn and clinical progress matter more."]
["Recent trend: Big wave of upgrades/price-target increases in Dec 2025 (RBC, Stephens, Mizuho, JPM, Morgan Stanley, Oppenheimer, B. Riley) following strong Phase 1b KT-621 atopic dermatitis data.", "Counterpoint: Wolfe downgraded to Peer Perform on 2026-01-06, citing catalyst scarcity and valuation concerns (bearish near-term framing).", "Latest notable update: Barclays (2026-01-27) assumed coverage with Overweight and raised PT to $133 (bullish long-term).", "Wall Street pros: strong clinical read-through on KT-621, perceived de-risking, and sizable market opportunity in I&I with convenient oral modality.", "Wall Street cons: valuation sensitivity after the run, potential catalyst gap until further trials/updates, and disagreement on near-term attractiveness (Wolfe skepticism)."]
